Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proinsulin II-GAD mRNA lipid particle aggregates
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Proinsulin II-GAD mRNA lipid particle aggregates is an experimental immunotherapeutic vaccine candidate designed for the prevention or delay of type 1 diabetes (T1D). It consists of mRNA encoding two key beta-cell autoantigens, proinsulin II (PI2) and glutamic acid decarboxylase (GAD), encapsulated within anionic lipid particle aggregates (LPAs). The mechanism involves the delivery of these autoantigens to the immune system in a manner that promotes immune tolerance and suppresses the autoimmune destruction of insulin-producing beta cells. In preclinical studies using non-obese diabetic (NOD) mice, the combination of PI2 and GAD mRNA-LPAs demonstrated superior efficacy in delaying the onset of diabetes compared to single-antigen formulations, particularly at the 18-week mark.
- Other names
- PI2-GAD mRNA LPAPI-2-GAD mRNA LPAPI 2-GAD mRNA LPAanionic mRNA lipid particle aggregates containing proinsulin II and GAD
Beyond the preview
Go deeper on proinsulin II-GAD mRNA lipid particle aggregates.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proinsulin II-GAD mRNA lipid particle aggregates.